Abstract
The human 22q11.2 chromosomal deletion is one of the strongest identified genetic risk factors for schizophrenia. Although the deletion spans a number of genes, the contribution of each of these to the 22q11.2 deletion syndrome (DS) is not known. To investigate the effect of individual genes within this interval on the pathophysiology associated with the deletion, we analyzed their role in sleep, a behavior affected in virtually all psychiatric disorders, including the 22q11.2 DS. We identified the gene LZTR1 (night owl, nowl) as a regulator of sleep in Drosophila. Neuronal loss of nowl causes short and fragmented sleep, especially during the night. In humans, LZTR1 has been associated with Ras-dependent neurological diseases also caused by Neurofibromin-1 (Nf1) deficiency. We show that Nf1 loss leads to a night-time sleep phenotype nearly identical to that of nowl loss, and that nowl negatively regulates Ras and interacts with Nf1 in sleep regulation. We also show that nowl is required for metabolic homeostasis, suggesting that LZTR1 may contribute to the genetic susceptibility to obesity associated with the 22q11.2 DS. Furthermore, knockdown of nowl or Nf1 in GABA-responsive sleep-promoting neurons elicits the sleep-fragmentation phenotype, and this defect can be rescued by increased GABAA receptor signaling, indicating that Nowl promotes sleep by decreasing the excitability of GABA-responsive wake-driving neurons. Our results suggest that nowl/LZTR1 may be a conserved regulator of GABA signaling and sleep that contributes to the 22q11.2 DS.
Introduction
Recent genome-wide association studies have identified chromosomal deletions and duplications that confer elevated risk of neuropsychiatric disorders [1, 2]. One of these, the 22q11.2 deletion, which spans 43 genes and occurs in 1 of every 2-4,000 births worldwide [3], is the most prominent known genetic risk factor for development of schizophrenia and is associated with high risk of neuropsychiatric disease [4, 5]. This deletion leads to a variety of phenotypes, including clinical manifestations such as congenital defects of the palate and heart, learning and cognitive disabilities, and sleep disturbances [6]. Sleep abnormalities are among the most common manifestations of neuropsychiatric disease [7], with up to 80% of autism and schizophrenia patients experiencing sleep disturbances [8, 9]. Individuals affected by the 22q11.2 deletion have a roughly 25-30% chance of developing schizophrenia or other psychiatric disorders that include sleep disturbances [10]. However, the possible contribution of each of the individual genes spanned by this deletion to this array of symptoms is not clear. Although certain disease phenotypes have been linked to single genes, such as TBX1, found to account for cardiac defects observed in 22q11.2 deletion carriers [11], the genes contributing to the 22q11.2-linked behavioral phenotypes such as sleep disturbance are not characterized.
Many schizophrenic patients exhibit abnormal sleep patterns such as delayed sleep onset, difficulty in maintaining sleep, and reduced overall amount of sleep [9]. Thus, genes that might play a role in schizophrenia and other behavioral symptoms of the 22q11.2 DS can potentially be identified by their sleep phenotypes. Sleep is an evolutionarily ancient conserved behavior that can be studied in lower organisms such as the fruit fly Drosophila melanogaster, a commonly used invertebrate model. Drosophila sleep has been rigorously examined and found to exhibit several of the mammalian hallmarks of sleep, such as sustained periods of quiescence, increased arousal threshold, and circadian and homeostatic regulation [12, 13]. Indeed, recent studies in Drosophila have identified genes associated with human neurodevelopmental and psychiatric disorders that disrupt sleep and circadian rhythm, such as the candidate autism-spectrum-disorder gene Cullin-3 (Cul3) [14, 15] and the candidate gene alicorn (alc) linked to the 1q21.1 deletion, another CNV that confers schizophrenia risk [16].
To identify genes that contribute to the behavioral deficits of the 22q11.2 DS, we examined the role in sleep of individual genes within this interval by knockdown of their Drosophila homologs in the nervous system of the fly. We identified night owl (nowl, CG3711), an ortholog of the human LZTR1 (leucine-zipper-like transcription regulator 1), as a modulator of night-time sleep in Drosophila. In humans, mutations in LZTR1 cause neurofibromatosis, a genetic disorder characterized by the growth of benign nervous-system tumors, that is most commonly known to result from mutations in Neurofibromin-1 (Nf1) [17, 18]. Here, we show that neuronal knockdown or mutation of nowl causes sleep disturbances including highly increased fragmentation of sleep and reduced total night-time sleep, similar to neuronal loss of Neurofibromin-1 (Nf1) in Drosophila. Nf1 is a negative regulator of the Ras signaling pathway and an activator of cAMP signaling [19, 20]; little is known about the function of LZTR1, except that its loss has been associated with neurofibromatosis. Interestingly, we find that nowl and Nf1 inhibit Ras signaling and interact genetically in the regulation of sleep in Drosophila. We find that nowl acts through gamma-aminobutyric acid (GABA)-responsive neurons expressing the ionotropic GABA receptor Rdl to maintain sleep. Furthermore, the sleep fragmentation exhibited by nowl mutant flies can be rescued by increased inhibitory signaling through this receptor. Because nowl knockdown phenocopies the sleep disturbances observed with neuronal Cul3 knockdown, we suggest that Nowl may interact with Cul3 and Nf1 in GABA-responsive neurons to regulate sleep. Thus, we have identified the 22q11.2-linked gene nowl, orthologous to human LZTR1, as a regulator of GABAergic signaling and night-time sleep in Drosophila. We suggest that LZTR1 is a promising candidate gene that may contribute to the sleep disturbances and behavioral symptoms seen in patients carrying the 22q11.2 deletion.
Results
Drosophila screening identifies an ortholog of human LZTR1 as a regulator of sleep
Sleep disturbance is a common manifestation of neuropsychiatric disorders in general and of the 22q11.2 DS. To determine which, if any, of the individual genes within this deletion might be required for normal sleep, we first identified the Drosophila orthologs of the human genes within the 22q11.2 interval. From the 43 genes lying within the 22q11.2 deletion, we identified 26 highly conserved orthologs in Drosophila (with a DIOPT score ≥ 6) [21] (Fig. 1A). Next, we conducted an RNA-interference (RNAi)-based screen to investigate whether the neuronal function of these Drosophila genes might be important for sleep, using the Drosophila Activity Monitor (DAM) system (TriKinetics), an automated beam-crossing locomotion assay that is the widely accepted standard for Drosophila sleep studies. In these assays, locomotor quiescence of longer than 5 minutes is taken to indicate a sleep-like state, comparable to mammalian sleep [12, 13]. To determine whether each identified Drosophila ortholog might play a role in sleep, we knocked each gene down using the nervous system-specific elav-GAL4 (elav>) line to drive RNAi expression. When possible, two independent RNAi lines targeting each gene were tested. The effectiveness of RNAi knockdown was enhanced by the co-expression of Dicer-2 (Dcr-2) [22]. Some RNAi constructs induced lethality when expressed pan-neuronally or displayed a non-inflating wing phenotype due to a gene disruption at the insertion site of the transgene [23]. These constructs were excluded from further analysis.
Pan-neuronal knockdown of several of the Drosophila 22q11.2 gene orthologs caused changes in total sleep and activity in adult males (Fig. 1B and 1C). Most of these manipulations led to a decrease in locomotor activity, with unchanged or increased sleep amount. Nervous system-specific knockdown of CG3808 (human TRMT2A), CG15908 (C22orf39), gonadal (DGCR6L), org-1 (TBX1), or slgA (PRODH) increased the total amount of sleep exhibited by males, while only the knockdown of CG3711, the Drosophila ortholog of LZTR1, caused a decrease in total sleep (Fig. 1A). In contrast, in females, neuronal knockdown of several genes led to decreased sleep, including CDC45L (human CDC45), CG13192 (GNB1L), CG13248 (SLC7A4), Crk (CRK), Es2 (DGCR14), Septin4 (SEPT5), and Ufd1-like (UFD1L) (S1A Fig.). Locomotor activity was affected upon knockdown of several 22q11.2 genes, with most leading to hypoactive phenotypes in both males and females (Fig. 1C and S1B Fig.). We decided to focus our further studies on LZTR1, the only tested gene whose knockdown led to reduced total sleep in combination with decreased locomotor activity in males.
nowl is required for night-time sleep
To investigate the role of LZTR1 in sleep, we examined the daily sleep pattern in animals with neuronal knockdown of LZTR1. In light of the reduced-night-time-sleep phenotype displayed by these animals, we chose to refer to this gene as night owl (nowl) (Fig. 2A). We found that nervous-system-specific knockdown of nowl (elav>nowl-RNAi) reduced night-time sleep compared to controls (elav>+ and nowl-RNAi/+, i.e., elav> and nowl-RNAi crossed to the w1118 genetic background for the RNAi line). To further investigate the effect of nowl loss, we examined the sleep phenotype of a homozygous-viable transposon-insertion mutant of nowl, Mi{ET1}CG3711MB12128 (for simplicity we hereafter refer to this allele as nowl1), which carries a 6-kb insertion into the third exon of nowl [24] (Fig. 2B-2D). Transcript levels of nowl have previously been shown to be drastically reduced in this mutant [25]. Like animals with neuronal knockdown, nowl1 mutants exhibited decreased sleep, primarily during the second part of the night, compared with the genetic-background controls (w1118/Y and +/Y, where “+” denotes a wild-type X chromosome and “Y” a wild-type Y chromosome). When sleep data was binned into day and night periods, it showed that nowl loss-of-function had a much larger effect on sleep during the night than during the day (Fig. 2E-2G). Males, but not females, exhibited a slight decrease in daytime sleep. On the other hand, night-time sleep dropped dramatically in both males and females. Loss of one copy of nowl (on the X chromosome) in females did not elicit a phenotype, suggesting that the nowl1 mutation is a recessive loss-of-function allele, consistent with the transcript-level defect previously reported [25]. To further confirm these results, we generated a CRISPR/Cas9-mediated deletion of the nowl coding sequence. Like neuronal knockdown and the nowl1 mutation, this deletion mutant (nowlKO) showed reduced night-time sleep (S2A Fig.). Taken together, these data indicate that nowl is important for proper sleep behavior, mainly during the night.
Although we observed a decrease in sleep levels overall, sleep levels in these flies still dropped in anticipation of light-dark and dark-light transitions, consistent with an intact circadian clock. To investigate whether nowl mutant males do maintain a normal circadian rhythm, adult animals entrained to a 12/12-hour light-dark cycle were kept under constant darkness (free-running conditions) for 8 days. The average circadian period of nowl1 mutants during these days was 23.5 hours, which is very similar to the corresponding controls’ free-running periods of 23.3 and 23.4 hours (S3A and S3B Fig.). This indicates that the nowl mutants can entrain to and maintain a normal circadian rhythm, suggesting that nowl function is not required for proper functioning of the circadian clock.
Loss of nowl disrupts sleep architecture and phenocopies lack of Cul3 and Nf1
Sleep-onset difficulties are common in psychiatric disorders [26]. Interestingly, both male and female nowl mutants exhibit increased sleep onset-latency, defined as the time between lights-off and the first sleep bout; that is, they take longer to fall asleep than controls (Fig. 2H and S2B Fig.). Control males’ latency was 40 minutes, while hemizygous nowl mutants on average took 70 minutes to fall asleep after lights-off. Homozygous nowl-mutant females also exhibited delayed sleep onset and on average remained active for 110 minutes before their first sleep episode, while control females fell asleep after 70 minutes. Sleep latency was also slightly increased in heterozygous nowl mutant females, in which the time to sleep onset was 90 minutes, intermediate between controls and homozygotes.
To confirm that the observed phenotype was related to sleep per se and not to altered activity patterns, we analyzed average activity during periods in which the animals were active in the night. Motion-bout activity was significantly reduced when nowl was knocked down in the nervous system compared to driver- and UAS-alone control genotypes (Fig. 2I), while nowl mutant flies also displayed reduced or unchanged motion-bout activity levels compared to control flies. This confirms that the observed sleep phenotype in animals lacking nowl is not the result of hyperactivity but rather is a specific sleep-disruption phenotype.
We next examined sleep fragmentation, which is associated with many psychiatric disorders and characterized by multiple short periods of sleep, i.e., an increased number of shorter sleep bouts. In the initial screen of genes within the 22q11.2 deletion, we found that knockdown of some genes including slgA (PRODH) and nowl/LZTR1 also altered the number and duration of sleep bouts (S4A-S4D Fig.). To further investigate whether loss of nowl plays a role in sleep maintenance following sleep initiation, we analyzed average sleep-bout number and length during day and night time in males lacking nowl. Knockdown of nowl in the nervous system using either of the two pan-neuronal drivers elav> and nSyb-GAL4 (nSyb>) caused a strong increase in fragmentation of night-time sleep, with a large decrease in sleep-bout duration combined with an increase in the number of sleep bouts, that was not observed during daytime (Fig. 3A-3D). Mutant flies carrying the nowl1 loss-of-function allele or the CRISPR-induced nowlKO deletion exhibited similar sleep-fragmentation patterns (S2C and S2D Fig.).
To more closely examine the sleep changes associated with night-time sleep fragmentation, we analyzed the distribution of sleep episodes by binning them by duration and calculating the time spent in each bin, for flies with reduced nowl expression in the nervous system and for nowl mutants, compared to control genotypes. Neuronal knockdown of nowl significantly increased the amount of time spent in short sleep bouts of 5-49 minutes, compared to control flies, which consolidated most of their night-time sleep into longer bouts of 150-720 minutes (Fig. 3E). A similar change was observed in nowl mutant flies (Fig. 3F). These data indicate that nowl is required for maintenance of proper sleep architecture in Drosophila.
Human LZTR1 was recently shown to function through the Cul3-based ubiquitin ligase complex, as a component of which it is suggested to mediate substrate specificity [27, 28]. Interestingly, Cul3 has also been implicated as a causative gene in psychiatric disorders [29] and has been shown to play an important role in Drosophila sleep [14, 15, 30]. We wondered whether nowl, like its ortholog LZTR1, might exert its effects on sleep through an interaction with Cul3. We therefore knocked down Cul3 pan-neuronally and analyzed sleep patterns, and found that Cul3 silencing in the nervous system caused a significant decrease in average sleep-bout duration and a significant increase in average sleep-bout number (S5A-S5D Fig.), during both day and night. This phenotype is similar to the sleep disruption caused by neuronal knockdown of nowl, which is consistent with an interaction between the two genes.
Mutations in human LZTR1 have been linked with schwannomatosis, a form of neurofibromatosis, a neurological disorder associated with sleep problems, mental disabilities, and psychiatric disorders that can also be caused by mutation of the Nf1 gene [17]. Nf1 encodes a GTPase that negatively regulates the Ras signaling pathway. We therefore asked whether nowl, like Nf1, affects Ras signaling, by measuring the levels of phosphorylated ERK (pERK), a downstream effector of Ras and marker of Ras-pathway activation. We found increased levels of pERK in heads from nowl mutants (Fig. 3G), indicating that the Ras pathway is overactivated. Thus, the Nowl protein does appear to be required for normal Ras-pathway inhibition, either directly, like Nf1, as a negative regulator of Ras, or indirectly. We next investigated whether Nf1 regulates sleep and found that neuronal knockdown of Nf1 reduces night-time sleep nearly identical to loss of nowl (Fig. 3H). These similarities are consistent with a sleep-regulating genetic interaction between nowl and Nf1.
Interactions between nowl and Nf1 suggest that they act on a common sleep-regulatory pathway
To investigate the possibility of genetic interaction between nowl and Nf1 in regulation of sleep, we overexpressed Nf1 in nowl-RNAi animals. In this test, a rescue of the nowl short-sleep phenotype would indicate that Nf1 functions downstream of nowl in a sleep-regulatory pathway. Neuronal overexpression of Nf1 partially rescued the loss of night-time sleep and sleep fragmentation caused by nowl knockdown (Fig. 4A-4C), suggesting that nowl and Nf1 may function in the same sleep-regulatory pathway, with Nf1 working downstream of Nowl. On the other hand, the double knockdown of Nf1 and nowl produced a reduction of day-time sleep that was not observed by single RNAi directed against either nowl or Nf1 alone (Fig. 4D). Next, we analyzed interaction by comparing effects in the single-hit knockdown compared to the double-hit knockdown of nowl and Nf1. As an initial step, we determined the efficiency and specificity of the RNAi-mediated knockdown using qPCR, and validated that the RNAi lines against nowl and Nf1 both significantly reduced target gene expression (S6A and S6B Fig.). In animals with double knockdown of nowl and Nf1 in the nervous system, the total daytime sleep amount decreased and fragmentation increased, compared to animals with single knockdown of either nowl or Nf1 and to the control, indicating that nowl and Nf1 interact in the regulation of daytime sleep (Fig. 4B). In animals with double knockdown of nowl and Nf1, total night-time sleep was reduced, similar to animals with single knockdown of nowl or Nf1, compared to the control (Fig. 4C). Simultaneous knockdown of nowl and Nf1 also increased night-time sleep fragmentation compared to the control. However, the effect of the double knockdown on night-time sleep parameters largely resembled the effect of Nf1 knockdown alone, suggesting an interaction between nowl and Nf1 in night-time sleep regulation that may be epistatic. The ability of Nf1 overexpression to partially rescue the loss of total night-time sleep and reduced sleep-bout duration during the night supports the notion that these two genes are functionally related and may converge on a common sleep-regulatory pathway.
Since our results indicated that Nowl inhibits the Ras pathway (Fig. 3G), we investigated the combined effect of nowl and Nf1 loss on the activation of the Ras pathway. Our data show that silencing nowl or Nf1 individually in the nervous system results in Ras overactivation, reflected in increased pERK levels (Fig. 4E). Consistent with this and with their genetic interaction in sleep regulation, the simultaneous knockdown of nowl and Nf1 activates the Ras pathway to an extent similar to knockdown of Nf1 alone. Together these effects indicate that nowl and Nf1 interact to suppress Ras-pathway activity.
To investigate the genetic interaction between nowl and Nf1 further, we compared the phenotypes of Nf1 and nowl trans-heterozygous mutants with those of the individual heterozygous mutants. The nowl gene is on the X chromosome, and males are therefore hemizygous; heterozygous effects can only be studied in females. Female animals heterozygous for either nowl or Nf1 displayed similar sleep patterns, with no significant loss of night-time sleep compared to the control (Fig. 5A-5C), whereas trans-heterozygous nowl+/- Nf1+/- mutant females exhibited a strong reduction in total sleep. Furthermore, trans-heterozygous nowl+/- Nf1+/- mutants displayed shorter sleep bouts, while animals heterozygous for mutations in either nowl or Nf1 alone displayed no change in sleep-bout duration compared to controls (Fig. 5D-5G). This indicates that trans-heterozygous loss of both nowl and Nf1 causes sleep fragmentation, further supporting the existence of a genetic interaction between nowl and Nf1 and a functional relationship between these two genes in the regulation of sleep.
Neuronal Nf1 and nowl are required to maintain metabolic homeostasis
Emerging evidence suggests that sleep is important for energy homeostasis and that insufficient sleep can lead to obesity [31]. A main function of sleep has been proposed to be an opportunity to replenish brain supplies of glycogen, which are depleted during periods of wakefulness [32, 33]. Since nowl and Nf1 loss decrease night-time sleep and thereby increase wakefulness, we analyzed glycogen levels in these animals. Consistent with the notion that sleep is important for maintaining glycogen levels, we found that indeed glycogen levels were reduced in animals with neuronal knockdown of nowl and Nf1 and in nowl mutants (Fig. 6A and 6B), which exhibits reduced night-time sleep. These data further suggest that neuronal function of nowl and Nf1 is essential to maintenance of glycogen stores, which may be related to their importance for getting enough sleep. We next analyzed body triglyceride levels since the 22q11.2 deletion is associated with increased risk of obesity, which is also linked to insomnia [34, 35]. We found increased organismal levels of triglycerides in flies with neuronal knockdown of nowl and in nowl mutants (Fig. 6C), suggesting that they exhibit increased adiposity like human 22q11.2 carriers. Taken together our results suggest that nowl is required in the nervous system to maintain organismal energy homeostasis, a function that might be related to its role in sleep considering the vital role of sleep in regulation of energy homeostasis.
Nf1 and nowl are required in GABA-responsive cells for night-time sleep
Changes in neuronal circuitry and neurotransmitter systems have been proposed to underlie several neuropsychiatric disorders. Signaling through GABA, in particular, has been found to be an important contributor to sleep in mammals [36]. GABAergic signaling has likewise been found to play a role in Drosophila night-time sleep initiation and maintenance [37-39]. Because we observed a strong disruption of both of these parameters in nowl knockdown and mutant flies, we wondered whether this gene might have a function in GABAergic signaling. To investigate this, we knocked down nowl in GABA-producing or GABA-responsive neurons using a panel of GAL4 driver lines. GABA-producing neurons were targeted using Gad1-GAL4 (Gad1>), which drives expression in neurons expressing the GABA-biosynthetic enzyme glutamate decarboxylase 1 (GAD 1). Rdl-GAL4 (Rdl>) was used to drive expression in neurons expressing the ionotropic GABAA receptor, while GABA-B-R2-GAL4 (GABA-B-R2>) was used to target neurons expressing the metabotropic GABAB receptor subtype 2. Furthermore, GABAergic innervation has been shown to regulate “clock” neurons expressing the Pigment Dispersing Factor (PDF) peptide, comprising a limited number of wake-promoting neurons, the small and large ventral lateral neurons (s-LNv and l-LNv, respectively) [40, 41]. To assess the function of nowl in these neurons, the Pdf-GAL4 (Pdf>) driver was used to drive expression in all PDF-expressing neurons, while the dimm-GAL4 (dimm>) driver allowed for knockdown in peptidergic neurosecretory cells including the l-LNvs, suggested to be the only sleep-regulatory neurons in this subset of cells [42]. Since global or neuronal loss of nowl leads to highly fragmented night-time sleep, we asked whether knockdown of nowl in any of these restricted neuronal subsets could elicit a similar effect on sleep maintenance. Interestingly, we found that knockdown of nowl using the Rdl> driver, thus specifically in GABAA-receptor-expressing neurons, caused a shortening of sleep bouts and an increase in their number during night, with an effect size similar to that seen with pan-neuronal knockdown (Fig. 7A-7B). Rdl encodes the Drosophila GABAA receptor, a ligand-gated chloride channel that mediates fast inhibitory effects of GABA, and it has been shown to affect several behaviors such as learning and sleep [39, 43]. Knockdown of nowl in other neuronal populations using the other drivers – targeting the GABA-producing cells, the GABAB-receptor-expressing neurons, and the PDF-expressing clock neurons – had no significant effect on night-time sleep-bout number or duration.
Since our data show that nowl interacts genetically with Nf1 in the regulation of night-time sleep (Fig. 4 and 5), we asked whether Nf1 also regulates sleep maintenance through specific effects in the GABAA-receptor Rdl-expressing neurons, like nowl. Consistent with the interaction of nowl and Nf1 in sleep regulation, knockdown of Nf1 in Rdl-expressing neurons produced a sleep fragmentation phenotype characterized by increased sleep bouts and decreased duration similar to loss of nowl in these GABA-responsive neurons (Fig. 7C-7D). Together these data suggest that nowl and Nf1 are specifically required in GABA-responsive Rdl-expressing neurons to maintain sleep after sleep onset. The lack of knockdown effect in the PDF-expressing neurons further supports the independence of the circadian clock from nowl function.
To investigate the expression of Nowl in the brain, particularly in GABAA-receptor Rdl-expressing neurons, we generated an anti-Nowl antibody. Colocalization of mCD8::GFP expression in the Rdl-expressing neurons with staining against Nowl shows that the mushroom bodies (MBs) express both the GABAA-receptor Rdl and Nowl (Fig. 7E). Interestingly, downregulation of Rdl in the α′/β′ neurons of the MBs causes sleep loss similar to knockdown of nowl [44]. Together these data are consistent with a model in which Nowl promotes night-time sleep via modulation of GABA signaling that regulates the activity of the Rdl-expressing mushroom-body α′/β′ lobes.
Increased inhibitory signaling through the GABAA receptor rescues nowl mutant sleep phenotype
Knockdown of nowl in GABAA-receptor Rdl-expressing neurons led to disruptions in sleep architecture, similar to the effects observed when decreasing inhibitory GABAergic signaling via Rdl. We therefore hypothesized that loss of nowl might affect sleep by reducing inhibitory GABAergic signaling effects in these neurons, thus disinhibiting them, which should promote wakefulness and reduce sleep [38, 39]. To address this possibility, we asked whether the RdlCB2 mutation would rescue the nowl mutant sleep phenotype. RdlCB2 mutant flies express a form of the GABAA receptor Rdl that is thought to exhibit reduced desensitization, leading to longer channel-opening duration, increased channel flux, and therefore increased neuronal inhibition downstream of GABA reception [37]. We rationalized that if loss of nowl increases neuronal excitability due to loss of GABAA-receptor signaling in Rdl-expressing neurons, the mutant RdlCB2 receptor might compensate for this and thereby rescue the sleep disturbance observed in nowl loss-of-function flies. Compared to control flies, introduction of one copy of the RdlCB2 allele significantly increased total sleep during the night, consistent with the expected effect of increased inhibitory GABA signaling. As we previously observed, nowl mutant flies displayed significantly decreased total sleep during the night. This effect was completely rescued in flies carrying both nowl1 and RdlCB2 (Fig. 7F). The addition of RdlCB2 caused a decreased number of longer night-time sleep bouts, eliminating the night-time sleep fragmentation induced by the loss of nowl function (Fig. 7G-7H). Taken together, these data suggest that increased inhibitory signaling through the GABAA-receptor Rdl largely rescues the sleep disturbances observed in nowl loss-of-function flies. We thus propose that nowl affects sleep by regulating the excitability of GABA-responsive Rdl-expressing neurons.
Discussion
Schizophrenia is a highly heritable disorder with a prevalence of 1% in the population [45, 46]. It encompasses a wide spectrum of symptoms, of which a major one is sleep disturbance [9]. The human 22q11.2 chromosomal deletion spans more than 40 genes, and children carrying this deletion are 20 to 25 times more prone to developing schizophrenia during adolescence [47]. To identify which 22q11.2 genes might underlie the syndrome and development of schizophrenia in human carriers, we screened for conserved genes within this deletion that are required for sleep in Drosophila by RNAi-induced knockdown in the nervous system. Neuronal knockdown of several genes each caused abnormal sleep patterns and activity in flies. In females, silencing of several genes including CDC45L (human CDC45), CG13192 (GNB1L), CG13248 (SLC7A4), Crk (CRK), Es2 (DGCR14), Septin4 (SEPT5), and UFD1-like (UFD1L) resulted in short-sleep phenotypes. Some of these genes have not previously been linked to behavioral deficits in schizophrenia. However, we observed that neuronal knockdown of CG13192 (human GNB1L) and slgA (PRODH) resulted in an increased number of sleep episodes that have a shorter length. PRODH catalyzes a step in the conversion of proline to glutamate, while GNB1L encodes a G-protein beta-subunit-like polypeptide [48, 49]; both genes have also been associated with schizophrenia and other mental disorders [48, 50-52]. In males, neuronal knockdown of several genes increased total sleep, while only nowl knockdown caused a decrease in total sleep. We show here that nowl, the conserved Drosophila homolog of the human LZTR1 gene contained within the 22q11.2 deletion, is required for night-time sleep initiation and maintenance. Mutation or neuronal knockdown of nowl decreased total sleep amount and caused highly fragmented sleep, especially during night-time, which is a phenotype frequently seen in mental illness [26]. In addition, nowl mutants exhibit highly delayed sleep onset (i.e., increased sleep-onset latency). Sleep-onset latency is a widely used measure in the study of human sleep disorders and psychiatric illnesses, including schizophrenia [26]. Accumulating evidence also indicates that getting enough sleep is important for the maintenance of energy balance and that reduced or poor sleep increases the risk of developing obesity [31]. Sleep is tightly connected to metabolic processes, and one proposed function of sleep is that it serves a key role in replenishing glycogen stores, which are depleted during wakefulness [32, 33]. Consistent with this notion, brain glycogen levels are highest during periods of sleep and decrease following rest deprivation in Drosophila [53]. Our findings of reduced glycogen levels in flies lacking nowl and Nf1 function agrees with the view that sleep disruption is associated with depletion of glycogen stores, although further studies are needed to determine whether this effect is linked to alteration in sleep or more direct effects on metabolism. Furthermore, our results show increased adiposity associated with loss of nowl in flies, suggesting that LZTR1 loss may contribute to the increased genetic susceptibility to develop obesity found in human 22q11.2 carriers [34]. Taken together the defects in sleep initiation and maintenance observed in nowl mutants suggest that LZTR1 loss may contribute to the symptoms observed in the 22q11.2 DS and in schizophrenia, including the increased incidence of obesity.
Delayed sleep onset and the short-sleep phenotype could be caused either by alterations in sleep homeostasis or by disturbances in circadian rhythm. Our data indicate that animals lacking nowl function exhibit a normal circadian rhythm, which suggests that their altered sleep is not related to problems with circadian sleep regulation. Furthermore, the night-time short sleep of animals with loss of nowl function is not a consequence of hyperactivity, which demonstrates that the sleep fragmentation observed in these animals is a specific sleep-disturbance phenotype. Since nowl encodes a highly conserved protein (51% identity and 67% similarity to the human LZTR1 protein), Nowl may govern an evolutionarily conserved mechanism that regulates night-time sleep in animals.
Human LZTR1 has been shown to interact with Cul3 in the Cul3 ubiquitin-ligase complex [27]. Cul3 in Drosophila has been associated with sleep and interacts physically in this regulation with Insomniac, another BTB/POZ-domain protein (like Nowl) that functions as a substrate adaptor in the Cul3 complex [15, 30]. Although Cul3 knockdown and nowl knockdown are phenotypically similar, Cul3 knockdown induces broader phenotypes including disruption of the circadian clock [14]. Future studies should determine whether Nowl regulates sleep through a physical interaction with Cul3.
Recent studies have found that LZTR1 may function in the Cul3 ubiquitin ligase complex to ubiquitinate Ras [27, 28], which has previously been implicated in sleep regulation [54]. Nf1 is an important regulator of Ras signaling, and mutations in Nf1 and LZTR1 both give rise to types of neurofibromatosis [17, 55]. We show that nowl is required for proper negative regulation of Ras signaling, similar to Nf1, and that nowl and Nf1 interact in the regulation of sleep. Heterozygotes for either nowl and Nf1 mutations exhibit normal sleep patterns, while nowl Nf1 trans-heterozygous animals display disrupted sleep architecture, including sleep fragmentation, indicating a genetic interaction. Furthermore, the reduction in total sleep and the fragmentation of night-time sleep caused by loss of nowl are partially rescued by Nf1 overexpression. Thus, these two genes may function in the same pathway, or both of them may act on a common element involved in sleep maintenance. Whether nowl and Nf1 regulate sleep through their effects on Ras activity will be an interesting question for future studies.
GABA neurotransmission is often altered in schizophrenic patients, and it is the main system that regulates night-time sleep [37, 41, 56, 57]. Since disruption of GABA signaling has also been shown to reduce night-time sleep in Drosophila, we asked whether nowl and Nf1 might function in GABA-producing or -responsive cells. We found that knockdown of nowl in Rdl-expressing GABA-responsive neurons led to strongly increased sleep fragmentation, similar to the effect of pan-neuronal nowl knockdown. The wake-promoting l-LNv “clock” neurons express Rdl and play a major role in regulating sleep [39]. When these neurons are artificially hyper-excited by the expression of the sodium channel NaChBac, which allows membrane depolarization to occur more readily, flies showed decreased levels of sleep and increased levels of arousal, especially during night-time [42]. Knockdown of Rdl in these cells increases sleep latency [38], while reduced GABAB-R-2 metabotropic receptor expression leads to reduced sleep during the late night [41]. Using RNAi-induced knockdown driven by the Pdf> and dimm> constructs, we found that nowl does not appear to function in these s-LNv clock neurons to regulate sleep, indicating that other Rdl-expressing neurons are involved in sleep-regulatory nowl activity. The mushroom bodies (MBs), which are required for olfactory associative learning and memory [58] and which also regulate sleep [59, 60], strongly express Rdl (Fig. 7E and [43]). A single pair of dorsal paired medial (DPM) neurons have been found to strongly promote sleep via GABAergic and serotonergic innervation of the mushroom bodies [44]. The MB α′/β′ neuronal population in particular are wake-promoting neurons that receive GABAergic input from the DPM neurons. Increased activation of the α′/β′ population decreases night-time sleep and increases sleep fragmentation [44]. Knockdown of Rdl in the α′/β′ neurons results in night-time sleep-loss phenotypes almost identical to those seen with knockdown of nowl pan-neuronally or specifically in the Rdl-expressing neurons, inducing increased sleep-bout numbers and reduced bout lengths, with a stronger effect during night-time [44]. Furthermore, we found strong enrichment of Nowl in Rdl-expressing MB neurons, consistent with Nowl’s functioning in the regulation of sleep via wake-promoting neurons in the mushroom body. Interestingly, nowl was also identified in an olfactory-learning screen, in which it was found to inhibit electric-shock-reinforced associative learning, consistent with a role for nowl in mushroom-body neuronal function [25]. Furthermore, we observed that Nf1 knockdown in Rdl-expressing neurons caused sleep reduction and fragmentation of night-time sleep similar to nowl knockdown, further supporting an interaction between Nf1 and nowl in the regulation of sleep. Investigating whether nowl and Nf1 do indeed regulate sleep via effects on GABA signaling in the mushroom bodies will be an interesting subject for follow-up studies.
It has been suggested that mutations in ion channels can lead to disrupted sleep by altering overall neuronal excitability [61]. One example of this is the gene Shaker, which encodes an α-subunit of a potassium channel that functions to regulate membrane repolarization after neuronal depolarization [62]. Loss-of-function mutations in this gene, and in its mouse orthologs, cause reduced sleep and shorter sleep episodes, without affecting circadian or homeostatic sleep drive [63]. Since sleep loss and fragmentation due to loss of nowl were partially rescued by increased GABAergic inhibition of Rdl-expressing neurons, we suggest that loss of nowl may alter neuronal excitability in wake-promoting Rdl-expressing neurons. It will be interesting to determine whether nowl directly affects the Rdl receptor or other substrates via Cul3 to regulate postsynaptic GABA signaling. Cul3 and its other interaction partner Insomniac are recruited to the postsynaptic compartment within minutes of acute glutamate-receptor inhibition [64]. These proteins mediate local mono-ubiquitination, which is important for homeostatic signaling in the postsynaptic compartment. The number of Rdl receptors expressed in a neuron, beyond the mere presence or absence of these receptors, has been suggested to be important in sleep regulation [39]. Furthermore, in humans, agonists of GABAA-type receptors are common treatments for insomnia [65], and a loss-of-function mutation affecting a GABAA receptor subunit causes a heritable type of insomnia [66]. Altered GABAergic signaling is believed to play a role in many neurodevelopmental disorders, and a mechanism that involves GABAA-receptor signaling may be a key factor underlying the pathophysiology of the 22q11.2 DS. Our findings suggest a contribution of nowl/LZTR1 – a 22q11.2 gene – in altered GABAergic neurotransmission and thus may provide a new direction for understanding the mechanisms underlying the observed neurodevelopmental phenotypes in the 22q11.2 DS and for developing therapeutic interventions against them.
Essentially all psychiatric disorders are associated with sleep disturbances. We have identified nowl as regulator of sleep in Drosophila. Mutations in its human ortholog LZTR1 have been implicated in several human diseases, such as schwannomatosis, glioblastoma, and the psychiatric disorders linked to the 22q11.2 DS. We suggest that the nowl/LZTR1 gene encodes a conserved regulator of sleep that interacts with Nf1 and that may contribute to the overall pathophysiology of the 22q11.2 DS. Further studies of Nowl may help understand the molecular mechanisms underlying both mental disorders and Schwann-cell tumors.
Materials and methods
Drosophila lines and maintenance
Drosophila larvae and adults of mixed sexes were raised on standard cornmeal medium (Nutri-Fly “Bloomington” formulation) at 25 °C under a 12:12 light/dark cycle with 60% humidity. The following fly lines were obtained from Bloomington Drosophila Stock Center (BDSC; Bloomington, IL): elav-GAL4; UAS-Dicer-2 (#25750), nSyb-GAL4 (#51635), Gad1-GAL4/CyO (#51630), Rdl-GAL4/CyO (#66509), Pdf-GAL4 (#6899), dimm-GAL4 (#25373), UAS-Dicer-2 (#24651), Mi{ET1}CG3711MB12128 (#29940), RdlCB2/TM6B, Tb1 (#35493), and UAS-mCD8::GFP (#4776). UAS-RNAi lines against orthologs of human 22q11.2 CNV-linked genes were procured from Vienna Drosophila Resource Center (VDRC; Vienna, Austria) and are listed in Supplementary Table 1. UAS-Cul3-RNAi (#109415), UAS-Nf1-RNAi (#109637), and the w1118 (#60000) genetic background line were also obtained from VDRC.
The GABA-B-R2-GAL4::p65 line carries a bacterial artificial chromosome (BAC) containing ∼80 kb of genomic sequence surrounding the GABA-B-R2 gene, in which the first coding exon of this gene was replaced with GAL4::p65 and associated terminator sequences; the remaining exons and introns are still present, with the assumption that they contain regulatory sequences, but they are no longer transcribed. This construct was built using recombineering techniques [67] in P[acman] BAC clone CH321-95N09 (Children’s Hospital Oakland Research Institute, Oakland, CA). Selectable markers (conferring kanamycin resistance and streptomycin sensitivity) were cloned from pSK+KanaRpsL [68] (AddGene plasmid #20871) and flanked with upstream GAL4 and downstream HSP70-UTR arms cloned from pBPGUw [69], a gift of G. Rubin. GABA-B-R2-specific homology arms were added by PCRing this landing-site cassette with the following primers (genomic sequence is in lower case): GABA-B-R2-GAL4-F: cgatatgcgc tattcacatt tagaatcgtt ttacagccca cgcggtcaac ATGAAGCTAC TGTCTTCTAT CGAACAAGC; GABA-B-R2-UTR-R: catcatcaga gattcactta atgaaatctt caagctaaac cctaactcac GATCTAAACG AGTTTTTAAG CAAACTCACT CCC. The homology-flanked landing-site cassette was recombined into the BAC (with kanamycin selection), and then full-length GAL4::p65-HSP70 amplified from pBPGAL4.2::p65Uw [70] (a gift of G. Rubin) was recombined into this site in a second recombination (with streptomycin selection). The recombined regions of the BAC were sequenced, and the sequence-verified BAC was integrated into the Drosophila genome at attP40 [71] by Genetic Services, Inc. (Cambridge, MA).
Identification of Drosophila orthologs
Drosophila orthologues of human 22q11.2 CNV-linked genes were identified using the “Drosophila RNAi Screening Center Integrative Ortholog Prediction Tool” (DIOPT), available at the website of the Drosophila RNAi Screening Center (DRSC), Harvard Medical School [21].
Sleep assays and analysis
The Drosophila Activity Monitor (DAM) system (TriKinetics, Inc., Waltham, MA) was used to measure locomotion over a 24-hour period. Adult flies were sorted by sex and collected in groups of 30 soon after eclosion. Collected flies were housed under standard conditions until the start of the experiment. Three-to-seven-day-old flies (either male only or female only, as indicated) were used for experiments, in which they were housed in 65-mm-long glass tubes containing a plug of food medium (5% sucrose and 2% agar in water) at one end and a cotton stopper at the other. Experiments were run in a behavioral incubator under a 12-hour light/12-hour dark cycle, and flies were allowed 12-24 hours to acclimatize prior to experimental start. Activity, determined as the number of beam crosses per fly per minute, was measured in one-minute periods, and episodes of sleep were defined as at periods of least 5 minutes of uninterrupted quiescence. Flies exhibiting less than 10 minutes of activity during either the entire light or dark phase were flagged as dead. The pySolo software package [72] and a custom MATLAB script (MATLAB R2016b, The MathWorks Inc, Natick, Massachusetts) written by Stanislav Nagy were used to analyze sleep dynamics. Sleep latency was calculated as the period from lights-off to the first sleep episode. Locomotor activity of male flies kept on a normal LD cycle for several days was monitored in constant darkness (DD) for 8 days to determine the length of the free-running circadian period. Data were aggregated into 30-minute bins and analyzed using the FaasX software [73], which uses Chi-Square test to calculate the period length.
Western blotting
For Western-blot analysis, ten male flies per genotype were frozen at -80 °C, vortexed, and sieved to obtain samples of heads. Heads were homogenized in 50 μl Laemmli Sample Buffer (Bio-Rad) containing 2-mercaptoethanol. Samples were denatured for 5 minutes at 95 °C and then centrifuged at maximum speed (17,000 g) for 5 minutes. Samples (20 μl) were loaded on 4-20% gradient polyacrylamide gel (Bio-Rad), and proteins were separated at 150 V for 30 minutes. Proteins were transferred onto PVDF membrane (Millipore), and the membrane was blocked for one hour in Odyssey Blocking Buffer (LI-COR). Primary antibodies (rabbit anti-phospho-ERK, Cell Signaling Technology #9101, 1:1000; mouse anti-α-tubulin, Sigma-Aldrich #T9026, 1:5000) were diluted in Odyssey Blocking Buffer containing 0.2% Tween 20, and the membrane was incubated overnight in this solution. Membranes were then rinsed and incubated for 40 minutes with secondary antibodies conjugated to infrared fluorophores (anti-mouse IRDye 680RD and anti-rabbit 800CW, LI-COR, 1:10,000), and staining was imaged using an Odyssey Fc scanner (LI-COR).
Anti-Nowl antiserum development and immunocytochemistry
To generate a Nowl antibody, a peptide corresponding to residues 123–141 of the parent protein (LRSSFKSSKRNKARKSAST) was used in a custom immunization protocol carried out by Genosphere Biotechnologies (Paris, France). Epitope specificity of the antiserum was confirmed by comparing wild-type (Rdl>GFP) and nowl-RNAi animals by immunostaining as well as by co-application of the pre-immune serum (S6C Fig.). For immunocytochemistry, primary antibodies used were polyclonal rabbit α-Nowl (1:200) and FITC-conjugated polyclonal goat anti-GFP (1:200; Abcam, #ab6662). Biotinylated anti-rabbit was applied (1:200; Vector Laboratories, #BA-1100), followed by Cy3-streptavidin (1:200; Jackson ImmunoResearch Laboratories, #016-160-084). Tissues were mounted on poly-L-lysine-coated 35-mm glass-bottomed dishes (MatTek Corporation, MA, USA) in Vectashield (Vector Laboratories Inc., CA, USA), and image acquisition was performed on an inverted Zeiss LSM800 confocal microscope with AiryScan (Zeiss, Oberkochen, Germany). Images were processed in CorelDraw X8 (Corel, Ottawa, Canada).
Transcript analysis by quantitative PCR
The efficiency of nowl and Nf1 RNAi-mediated gene knockdown was analyzed using quantitative RT-PCR (qPCR). Heads from adult male flies expressing neuronal RNAi against nowl or Nf1, along with driver- and RNAi-alone controls, were collected, and total RNA was extracted from 10 heads per sample using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. cDNA was reverse transcribed from total RNA using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher #4368814), and used a template for qPCR with the QuantiTect SYBR Green PCR Kit (Fisher Scientific #204145) and an Mx3005P qPCR System (Agilent Technologies). Levels of target gene expression was normalized against RpL32. Precomputed oligo pairs from the FlyPrimerBank was used for target gene primers. Primers were: GGAGGATCGGGATGTAGTATGG and CGTGTAGGAGGTGAAGTCCAC for nowl; AGTATCTGATGCCCAACATCG and CAATCTCCTTGCGCTTCTTG for Nf1; and CTTTTGGCACGTTTCGAGGAT and GGTAGCGCGATATGTGGATCAG for RpL32.
Measurements of glycogen and triglycerides
For triglyceride and glycogen assays, one-week old adult males flies were collected and frozen at -80 °C in groups of three animals until assayed. Animals were homogenized in 80 µl PBS + 0.5% Tween using a Tissue Lyser LT (Qiagen) with small steel beads. For triglyceride measurements, 8 µl of the homogenate was added to 80 µl Free Glycerol Reagent (Sigma, F6428) and 20 µl Triglyceride Reagent (Sigma, T2449), and reactions were incubated at 37 °C for 10 minutes with agitation, before being read at 540 nm absorbance. For glycogen measurements, 6 µl homogenate was mixed with 94 µl Glucose Oxidase (GO) reagent from the Glucose (GO) Assay Kit (Sigma, GAGO20) containing 1 µl (0.3 U) of amyloglucosidase (Sigma, A7420-5MG) to determine total glucose + glycogen. Another 6 µl homogenate was mixed with 94 µl GO reagent alone (without the amyloglucosidase) to determine free glucose. Reactions were incubated at 37 °C for 20 minutes, after which 66 µl of 12-N sulfuric acid was added to stop and complete the reaction before absorbance was measured at 540 nm. Absorbance was measured using an EnSight multimode plate reader (PerkinElmer), and values were standardized against readings for a range of known concentrations.
Statistics
GraphPad Prism software was used for statistical analysis. Data was tested for normality using D’Agostino-Pearson normality test. One-way ANOVA with Dunnett’s multiple comparisons was performed to establish differences between control and several genotypes for normally distributed data, while Kruskal-Wallis test with Dunn’s post-hoc testing was used for non-normally distributed data. Statistical significance was set at p≤0.05.
Footnotes
Co-first-authorship removed; Typographical and formatting errors fixed.